SPRAVATO® Patient Experience: What to Expect During and After Treatment
Starting SPRAVATO® raises practical questions that the clinical literature answers incompletely. This post addresses what the treatment actually feels like, what to expect after sessions, and how to know if it is working.
Quick answer
SPRAVATO (esketamine) produces dissociative and perceptual effects during the two-hour in-session monitoring period that resolve before discharge. These in-session effects are expected, not dangerous, and their intensity varies by dose and individual. Most patients describe the effects as unusual but manageable. Antidepressant response typically begins within the first one to two weeks of induction.

What Happens During a SPRAVATO® Session
Understanding what a SPRAVATO session involves reduces the anxiety of the unknown that some patients experience before their first session. Here is an accurate account of what the experience typically involves.
Arrival and preparation. You arrive at the ETX Psychiatry clinic approximately 15 minutes before your scheduled session time. Staff confirm your identity, review the session procedure, check your blood pressure and other vital signs, and prepare the SPRAVATO device. You should not eat for at least two hours before the session to reduce nausea risk, and should not drink large amounts of fluids. You will have arranged transportation for the rest of the day — driving is not permitted for the remainder of the session day regardless of how you feel at discharge.
Self-administration. SPRAVATO is self-administered as a nasal spray. Clinical staff instruct and observe but do not administer it themselves (REMS program requirement). The device delivers the medication to both nostrils in a standardized dose. Multiple doses may be used in one session depending on the prescribed dose (56mg or 84mg).
The monitoring period. Following administration, you remain in the clinical setting for at least two hours. During this period, you will likely experience dissociation — a sense of detachment from your environment and body that ranges from mild to significant. Other common in-session effects include: dizziness or unsteadiness (which is why you remain seated); nausea that is usually mild and often resolves within the first 30–60 minutes; altered visual or auditory perception (colors may seem more vivid, sounds may seem different); slowed thinking or difficulty maintaining a train of thought; and floating or dreaming sensations. These effects are expected, not dangerous, and they resolve over the two-hour period for the majority of patients.
Some patients find the dissociative period uncomfortable or disorienting, particularly in the first one or two sessions when it is unfamiliar. Others find it neutral or even pleasant. Having a recliner or comfortable chair, being able to listen to calming music, and knowing in advance that the sensations are temporary and will resolve all help manage the experience. ETX Psychiatry clinical staff are present throughout and can provide reassurance.
After the Session
The SPRAVATO REMS program requires a minimum two-hour monitoring period, after which a clinician assesses whether the patient is safe to leave. The discharge assessment specifically evaluates whether the dissociative effects have resolved to the point of safe departure — not whether you feel fully baseline.
Same-day functioning. Most patients describe the remainder of the session day as muted — reduced sharpness, fatigue, a dreamlike quality that persists for several hours after discharge. Driving is absolutely not permitted. Complex cognitive tasks (returning to demanding work, important decision-making, operating machinery) should be avoided for the rest of the session day. Most patients go home, rest, and feel closer to their usual selves by the following morning.
Day after the session. The vast majority of patients feel at or near their normal baseline by the morning after the session. The day-after experience is generally not impaired, and work, driving, and normal activities can resume unless your provider has specified otherwise.
Nausea management. Nausea is the most common reason for early session discomfort. The standard approach is an antiemetic (anti-nausea medication) given before the session for patients who experience significant nausea. If nausea has been a problem in prior sessions, raise it with your provider before the next one — pre-medication significantly improves tolerability.
Blood pressure monitoring. SPRAVATO transiently elevates blood pressure during and after administration. Clinical staff monitor blood pressure during the session and before discharge. Patients with pre-existing hypertension require closer monitoring and sometimes dose adjustment.

Recognizing Treatment Response
One of the most frequently asked questions about SPRAVATO is: how will I know if it is working? The answer involves both what to look for and when to expect it.
Timeline. SPRAVATO produces faster antidepressant onset than conventional antidepressants. Many patients notice improvement in mood, energy, or outlook within the first one to three sessions (the first one to two weeks of twice-weekly induction). This rapid onset is one of SPRAVATO’s clinical advantages over oral antidepressants and reflects its glutamatergic mechanism of action, which produces acute synaptogenesis rather than relying on the slower adaptive changes that underlie conventional antidepressant response.
What improvement looks like. For most patients, the first signs of response are subtle: slightly more energy in the morning, slightly more interest in activities that were completely anhedonic, slightly less heaviness in mood. Full response — meaningful and sustained reduction in depressive symptoms — typically develops over the four-week induction period. Tracking specific symptoms with a simple weekly rating (mood, energy, interest, sleep) helps identify response that might otherwise be dismissed as normal day-to-day variation.
Inadequate response. If there is no meaningful improvement after the full four-week induction (eight sessions), the treatment plan is reviewed. Inadequate response to SPRAVATO does not exhaust treatment options — TMS, ECT, and medication augmentation strategies remain available. ETX Psychiatry discusses the plan comprehensively if induction response is inadequate.
Call (430) 288-5800 to schedule a SPRAVATO evaluation. We serve Tyler, Longview, Lufkin, Nacogdoches, and East Texas patients who need this treatment without traveling to a major city. We accept Medicare, Aetna, BCBS, Cigna, Optum, UHC, UMR, and Ambetter. 100 Independence Pl, Suite 405, Tyler, TX 75703.

Practical Preparation for Your First Session
Patients preparing for their first SPRAVATO session often want to know how to set themselves up for the best possible experience. Several practical steps help.
Before your session: eat a light meal at least two hours before the appointment; arrange transportation with a specific driver (not rideshare apps where availability is uncertain); wear comfortable clothing; bring something calming to listen to on headphones if you prefer music during the session; and have your pharmacy’s phone number ready in case any prescriptions need updating.
During your session: let clinical staff know if nausea or any other effect feels severe rather than managing it silently; don’t resist the dissociative effects by trying to stay sharp — allowing the experience to unfold as it comes is generally described as more comfortable than fighting it; use calming music or rest rather than trying to work or maintain normal cognitive function during the monitoring period.
After your session: go home and rest; do not drive or make important decisions; eat a normal meal if you feel able; note any observations about the session experience (side effects, overall impression) to share with your provider at the next session or follow-up visit.
ETX Psychiatry provides thorough orientation to the SPRAVATO experience before the first session. Patients who feel well-prepared for what to expect report better first-session experiences. Call (430) 288-5800 to schedule your evaluation.
Key Takeaways
- SPRAVATO sessions involve self-administration followed by a required two-hour monitoring period during which dissociative effects occur and resolve
- Dissociation, dizziness, and altered perception are expected in-session effects — not side effects to fear but temporary effects to know in advance
- Driving is not permitted the remainder of the session day; most patients feel at or near baseline by the morning after the session
- Antidepressant response often begins within the first one to three sessions — significantly faster than conventional antidepressants
- Nausea is manageable with pre-session antiemetic medication — if it has been a problem, raise it with your provider before the next session
Frequently Asked Questions
Does SPRAVATO feel like being high?
The in-session dissociative effects are distinct from recreational drug intoxication. Most patients describe a floating, dreamlike, or detached quality that is unusual but not like alcohol or recreational drug intoxication. The experience varies by individual and dose. Clinical staff are present throughout.
Is it safe to be alone during a SPRAVATO session?
SPRAVATO sessions are conducted at a certified clinical facility with staff present throughout. You are not alone during the session or monitoring period. The REMS program specifically requires in-clinic administration with monitoring for safety reasons.
How long do the dissociative effects last?
The dissociative effects of SPRAVATO typically peak within 30–45 minutes after administration and resolve substantially within the two-hour monitoring period for most patients. Some mild residual effects may persist for several additional hours after discharge.
Can I drive myself home after a SPRAVATO session?
No. Driving is not permitted for the remainder of the session day regardless of how you feel at discharge. The REMS program requires that patients arrange a specific driver before each session. Rideshare is acceptable if a specific driver is confirmed in advance.
Will SPRAVATO make me feel better right away?
Many patients notice early improvement within the first one to three sessions — significantly faster than oral antidepressants. The improvement is often subtle initially (more energy, slightly less anhedonia) and builds over the four-week induction. Not every session produces immediate mood improvement; the cumulative effect builds over the induction period.
What happens if I feel very anxious during the session?
Let your clinical provider know immediately. Anxiety during the dissociative period, particularly in the first sessions, is not uncommon and can be addressed with reassurance, repositioning, or other supportive measures. Knowing in advance that the effects are temporary and that staff are present helps most patients manage first-session anxiety.
Does SPRAVATO interact with my other medications?
SPRAVATO can interact with several medication classes including benzodiazepines (sedation risk), stimulants (cardiovascular effects), and monoamine oxidase inhibitors (contraindicated). Your full medication list is reviewed before SPRAVATO treatment is initiated. Inform your provider of any medication changes during your treatment course.
What if I miss a SPRAVATO session?
Missing occasional sessions during induction does not eliminate treatment benefit but may affect the overall response. Discuss any scheduling conflicts with your provider in advance. During maintenance, the frequency of sessions is already reduced, and occasional missed sessions have less clinical impact.